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Introduction
Colorectal cancer (CRC) is the most prevalent malignancy of the 
digestive tract in men and women in developed countries. CRC is 
diagnosed approximately one million times per year worldwide, 
and over half a million patients die from this disease annually.1–3 
The surgical removal of primary CRC is the preferred therapeu-
tic option and the only treatment that can provide long-term 
disease-free survival.4 However, 20–50% of the patients that do 
not have evidence of metastatic disease at the time of resection 
develop liver metastases within 5 years.5 This indicates that these 
patients either have undetectable micro-metastases or circulating 
tumor cells that can grow out at distant sites, even though sur-
gery successfully removes the primary neoplastic lesion.
The surgical resection of primary colorectal cancer is associated with an enhanced risk of liver metastases. Moreover, 
bacterial translocation or anastomic leakage during resection has been shown to correlate with a poor long-term 
surgical outcome, suggesting that bacterial products may contribute to the formation of metastases. Driven by these 
premises, we investigated the role of the bacterial product lipopolysaccharide (Lps) in the generation of liver metastases. 
Intraperitoneal injection of Lps led to enhanced tumor-cell adhesion to the rat liver as early as 1.5 h post-administration. 
Furthermore, a rapid loss of the expression of the tight junction protein zonula occludens-1 (ZO-1) was observed, 
suggesting that Lps disrupts the integrity of the microvasculature. Lps addition to endothelial-macrophage co-cultures 
damaged endothelial monolayers and caused the formation of intercellular gaps, which was accompanied by increased 
tumor-cell adhesion. These results suggest that macrophages are involved in the endothelial damage resulting from 
exposure to Lps. Interestingly, the expression levels of of ZO-1 were not affected by Lps treatment in rats in which liver 
macrophages had been depleted as well as in rats that had been treated with a reactive oxygen species (ROs) scavenger. 
In both settings, decreased tumor-cell adhesion was observed. Taken together, our findings indicate that Lps induces ROs 
release by macrophages, resulting in the damage of the vascular lining of the liver and hence allowing increased tumor-
cell adherence. Thus, peri-operative treatments that prevent the activation of macrophages and—as a consequence—
limit endothelial damage and tumor-cell adhesion may significantly improve the long-term outcome of cancer patients 
undergoing surgical tumor resection.
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It has previously been demonstrated that surgery can paradoxi-
cally contribute to tumor recurrence and liver metastasis develop-
ment.6–8 First, free circulating tumor cells have been detected in 
the peripheral blood of CRC patients prior to surgery.9 Moreover, 
the number of circulating tumor cells has been shown to increase 
during, or shortly after, resection in, both peripheral and portal 
blood, suggesting that the surgical handling of the tumor may 
result in tumor-cell shedding and dissemination.9,10 Second, 
previous studies have proved that surgery leads to the enhanced 
adhesion of tumor cells, which can proliferate and generate 
metastases, suggesting that surgical trauma augments metasta-
sis outgrowth.7,8,11,12 Interestingly, it has also been shown that 
patients exhibiting bacterial translocation after surgical tumor 
resection have significantly reduced disease-free survival.13 In line 
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co-cultures. In addition, we determined the biological activity of 
LPS in the rat liver and its role in tumor-cell adhesion in vivo.
Results
LPS stimulates tumor-cell adhesion in the rat liver by disrupt-
ing organ integrity. To investigate the effects of LPS on tumor-
cell adhesion in the liver, rats were intraperitoneally injected 
with PBS or LPS, followed by the inoculation of tumor cells into 
the portal circulation. The number of tumor cells persisting in 
the liver of rats that had been pre-treated with LPS was signifi-
cantly increased 1.5 h after injection of LPS, as compared with 
the amount of tumor cells found in the liver of PBS-treated rats 
(Fig. 1A and B). Immunofluorescent staining of rat liver samples 
demonstrated that the administration of LPS results in decreased 
expression of the tight junction protein zonula occludens-1 
(ZO-1; Figure 1C), pointing to a situation of endothelial stress 
and loss of liver microvascular integrity.
Because our previous findings suggest that macrophages pro-
mote tumor-cell adhesion by disrupting sinus endothelial barri-
ers,11 we studied the effects of LPS-stimulated macrophages on 
endothelial cells. Because macrophages and sinus endothelial cells 
are in close proximity to each other in the liver, we developed a 
model allowing us to study endothelial cells and macrophages in 
intimate contact (Fig. 2A). Confluent endothelial cell monolay-
ers were cultured on the upper side of transwells membranes, and 
macrophages on the lower side. Neither the incubation of human 
with this notion, the treatment of mice with bacterial endotoxins 
reportedly promoted the development of lung and liver metasta-
ses.14,15 These data suggest that bacterial spillage during surgery 
may contribute to the growth of metastases.
Bacterial products such as lipopolysaccharide (LPS, an impor-
tant component of the outer membrane of Gram-negative bacte-
ria) have been detected in the plasma of surgerized patients.16,17 
The concentration of LPS in the peripheral blood was found to 
increase 1 h after surgery and to normalize 24 h later. Elevations 
in the circulating levels of LPS were accompanied by intestinal 
permeability, suggesting that the epithelial barrier was partially 
compromised upon surgery.18 Finally, the translocation of viable 
bacteria from the gut lumen to local mesenteric lymph nodes has 
been documented in CRC patients undergoing colectomy.13,19,20
It has recently been demonstrated that LPS is detected by 
human CRC cells via Toll-like receptor 4 (TLR4), leading to 
enhanced cell adhesion.14 In addition, LPS can activate potent 
immune responses through TLRs that are expressed by a wide 
variety of cells from the immune system, including macrophages.21 
Previously, we have shown that macrophages can release reactive 
oxygen species (ROS) upon surgery.11 ROS have been reported 
to disrupt the endothelial barrier, leading to vascular perme-
ability in tissues, as well as enhanced tumor-cell adhesion in the 
liver.22–24 Because macrophages express TLR4, we hypothesized 
that they may play a role in the pro-metastatic activity of LPS. In 
the present study, we investigated the effects of LPS-stimulated 
macrophages on endothelial integrity in macrophage-endothelial 
Figure 1. Lps stimulates tumor-cell adhesion in the liver by disrupting endothelial integrity. (A) Tumor cells in the livers of rats that had been treated 
with pBs or Lps and were sacrificed 1.5 h after tumor-cell inoculation. Red: DiI-labeled cc531s, blue: cell nuclei, arrowheads point to cc531s cells. 
(B) Quantification of tumor cells in the livers of rats after pBs or Lps treatment. n = 4 per group; *p < 0.05. (C) ZO-1 staining in the livers of rats that had 
been treated with pBs or Lps and were sacrificed after 1.5 h. Green, ZO-1; blue, nuclei.
investigated tumor-cell adhesion after incubation of HUVEC-
macrophage co-cultures with LPS. Intercellular gaps in the endo-
thelial monolayers that were formed upon LPS administration, 
contained high numbers of adherent tumor cells (Fig. 2D, right 
panel). In contrast, no tumor cells attached to endothelial mono-
layers were detected in the absence of LPS (Fig. 2D, left panel).
Since these data reflected the activation of macrophages by 
LPS, we used scanning and transmission electron microscopy 
(SEM and TEM, respectively) to visualize the effects of LPS 
umbilical vein endothelial cells (HUVECs) with 100 ng/mL LPS 
nor the co-culture of HUVECs with macrophages in the absence 
LPS affected endothelial integrity (Fig. 2B). However, the addi-
tion of 10 ng/mL LPS to HUVEC-macrophage co-cultures dis-
rupted the integrity of endothelial monolayers and promoted 
the formation of intercellular gaps between endothelial cells, 
which were further increased when 100 or 500 ng/mL LPS was 
added. Addition of the LPS inhibitor polymixin B (PMB) sig-
nificantly prevented endothelial cell damage (Fig. 2C). Next, we 
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Figure 2. Lps leads to endothelial damage and causes enhanced tumor-cell adhesion. (A) schematic overview of the co-culture of hUVec and mac-
rophages (MΦ) in vitro. (B) hUVec-macrophages co-cultures were incubated with different concentrations of Lps. Red, hUVecs fluorescently stained 
with Ulex-Rhodamin; blue, cell nuclei. (C) Quantification of damaged endothelial area (%). *p < 0.05; **p < 0.01; ***p < 0.001. (D) Tumor-cell adherence 
after exposure of hUVec-MΦ co-cultures to control or Lps. Red: hUVecs, blue: cell nuclei, light blue: sW620 tumor cells. Dotted lines indicate damaged 
areas without endothelial cells.
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received LPS were tightly attached to the substrate and widely 
spread, pointing to a robust activation (Fig. 3A, right panels). 
Moreover, LPS-stimulated macrophages formed a continuous 
monolayer after 2 h, while their PBS-treated counterparts did not 
do so and persisted as non-confluent populations. Furthermore, 
PBS-treated macrophages contained no intracellular vacuoles 
and showed almost no filopodia (Fig. 3B, left panel), reflecting 
a reduced cellular activity. In contrast, LPS-stimulated macro-
phages contained several intracellular vacuoles and exhibited 
multiple filopodia, indicating a high cellular activity (Fig. 3B, 
right panel). Thus, incubation of macrophages with LPS caused 
their rapid activation. This is consistent with our in vivo data 
showing increased tumor-cell adhesion as early as 1.5 h after 
tumor-cell injection in rats that were pre-injected with LPS 
(Fig. 1A and B).
To investigate the role of macrophages in tumor-cell adher-
ence in the rat liver upon in vivo LPS administration, we used 
control rats and rats in which liver macrophages (also known as 
Kupffer cells, KCs) had been depleted by injection of clodronate-
containing liposomes.25 The absence of liver macrophages or 
newly recruited monocytes upon treatment clonodrate-bearing 
liposomes was confirmed by staining for ED2 (a marker for tis-
sue-resident macrophages, data not shown) and ED1 (a marker 
of newly recruited monocytes, data not shown). All animals were 
treated with LPS and tumor cells were injected into the portal cir-
culation. The number of tumor cells in the livers of KC-depleted 
rats that had been pre-treated with LPS was drastically decreased 
as compared with the number of tumor cells found in the livers of 
control rats pre-treated with LPS 1.5 h after tumor-cell inocula-
tion (Fig. 4A and B). Moreover, higher expression levels of ZO-1 
were observed in the livers of KC-depleted rats receiving with LPS, 
as compared with control rats similarly treated (Fig. 4C). Thus, 
macrophages appear to regulate the adherence of tumor cells in 
the livers of LPS-treated animals by disrupting organ integrity.
LPS stimulation of macrophages leads to damaged endothe-
lial layer through ROS production. It has previously been shown 
that ROS induce endothelial damage.11 Therefore, we investi-
gated whether the damage to endothelial monolayers in LPS-
treated co-cultures of HUVECs and macrophages was mediated 
by ROS. The incubation of co-cultures with 100 ng/mL LPS 
resulted in an endothelial damage that was reduced in the pres-
ence of the ROS-scavenging enzymes superoxide dismutase 
(SOD) or catalase. Moreover, endothelial damage was virtually 
abolished when SOD and catalase were employed in combina-
tion (Fig. 5A and B).
Next, we investigated the role of ROS in LPS-induced tumor-
cell adhesion in vivo by treating rats with the anti-oxidant eda-
ravone, which is clinically used to treat ischemic stroke.26,27 
Animals were treated with PBS, edaravone, LPS or LPS plus eda-
ravone. The liver of rats that were treated with LPS contained 
a significantly higher number of tumor cells than the livers of 
PBS- or edaravone-treated rats (Fig. 6A and B). Importantly, sig-
nificantly lower numbers of tumor cells were observed in livers 
of animals which were treated LPS plus edaravone, as compared 
with rats receiving LPS only. Furthermore, the expression levels of 
ZO-1 did not decreased in the livers of rats that had been treated 
stimulation on macrophages. After 30 min incubation with PBS, 
macrophages showed some extent of adherence to the culture 
substrate (Fig. 3A, left panels). Conversely, macrophages that 
Figure 3. Lps stimulates rapid macrophage activation. (A) human 
macrophages were incubated with either pBs or Lps and cells were 
analyzed by seM at different time points. (B) Macrophages were treated 
with pBs or Lps for 2 h and then analyzed by TeM. Representative 
pictures are shown.
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had been treated with LPS. This indicates that LPS disrupts liver 
microvasculature. It has previously been shown that the expo-
sure of the sub-endothelial ECM in the liver vasculature leads to 
increased tumor-cell adhesion.8 Therefore, we propose that LPS 
causes endothelial damage in vivo as well, allowing free circu-
lating tumor cells to adhere to exposed ECM. This hypothesis 
is supported by the results of a previous study, demonstrating 
that an increased binding of polymorphonuclear cells (PMNs) 
to the liver microvasculature upon LPS treatment was due to an 
altered interaction with the ECM.31 As we also observed signifi-
cant accumulation of PMNs in the livers of rats receiving LPS 
(data not shown), it is likely that both PMNs and tumor cells use 
with LPS plus edaravone (Fig. 6C). Altogether, these 
results indicate that LPS-induced tumor-cell adhe-
sion in the liver is a ROS-dependent process.
Discussion
The surgical resection of primary tumors is the pre-
ferred therapeutic option for CRC patients and can 
provide long-term disease-free survival. However, 
surgical trauma has been paradoxically correlated 
with development of liver metastases.8 In addition, 
it has been demonstrated that exposure to LPS pro-
motes the formation of lung and liver metastases.14,15 
The resection of part of the colon may potentially 
be accompanied by bacterial contamination, as sug-
gested by the detection of increased LPS concentra-
tions in the portal and peripheral blood of patients 
subjected to colectomy. Moreover, patients exhibit-
ing bacterial translocation from the gut lumen to 
mesenteric lymph nodes have a comparatively short 
disease-free survival,13 indicating that the exposure 
to bacterial products like LPS may lead to poor clini-
cal outcome. In the current study, we demonstrated 
that LPS promotes tumor-cell adhesion in the livers 
of rats as early as 1.5 h after the inoculation of tumor 
cells via the portal vein. It has recently been shown 
that LPS can directly increase CRC cell adhesion 
via a TLR4-dependent mechanism.14 This promotes 
the functional activation of β1 integrin, which is 
an important adhesion molecule specific for the 
extracellular matrix (ECM). However, whereas β1 
integrin appeared to be essential for the adhesion of 
CC531s CRC cells to damaged peritoneal surfaces,7 
it was not required for adherence to the liver vas-
culature.8 This suggests that our findings cannot be 
explained by a direct effect of LPS on CRC cells.
Upon binding to TLR4 on the surface of cells from 
the immune system, LPS also operate as a potent acti-
vator of inflammatory and immune responses.21,28 
The liver contains resident macrophages, which are 
in intimate contact with sinusoidal endothelial cells 
and capable of releasing ROS upon stimulation with 
LPS.29,30 In line with previous results,29,30 we also 
observed that LPS promote the activation of mac-
rophages. Previously, inflammatory mediators such as LPS have 
been suggested to induce the M1 macrophage phenotype, cor-
responding to so-called “classically-activated” macrophages that 
are able to produce and release ROS.28 It is therefore likely that 
rats treated with LPS will develop macrophages with an M1-like 
phenotype. In our hands, the activation of macrophages by LPS 
resulted in damaged endothelial monolayers in vitro, potentially 
resulting in the exposure of the sub-endothelial ECM. Moreover, 
the addition of tumor cells to LPS-treated HUVEC-macrophage 
co-cultures demonstrated that tumor cells preferentially attach 
to intercellular gaps, rather to endothelial cells. Furthermore, we 
detected a decreased expression of ZO-1 in the livers of rats that 
Figure 4. Lps-induced tumor-cell adhesion is Kupffer cell (Kc)-dependent. (A) Tumor 
cells in the livers of control or Kc-depleted rats that were treated with Lps. Red: DiI-
labeled cc531s, blue: cell nuclei, arrow heads point to cc531s cells. (B) Quantification 
of tumor cells in the livers of control or Kc-depleted rats that were treated with Lps. 
n = 4 per group; ***p < 0.001 (C) ZO-1 staining in the livers of control or Kc-depleted 
rats that were treated with Lps. Green: ZO-1, blue: cell nuclei.
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LPS-induced endothelial damage may promote the 
adherence of tumor cells in the liver and worsen 
disease outcome.
The damage to endothelial monolayers medi-
ated by LPS was prevented by the addition of ROS-
scavenging enzymes, indicating an essential role for 
ROS in this process. Both PMNs and macrophages 
can be activated by LPS and are potent ROS pro-
ducers.21,33 Therefore, these cells may contribute 
to endothelial damage in vivo. The depletion of 
liver macrophages as well as the administration 
of the antioxidant edaravone drastically decreased 
tumor-cell adherence in the liver and preserved 
ZO-1 expression, demonstrating an essential role 
for ROS production by macrophages. Of note, 
an impairment of ROS-scavenging systems has 
been observed both in cancer patients and tumor-
bearing mice. Catalase activity, which neutralizes 
H
2
O
2
, was decreased in patients bearing rectal, 
gastric, pancreatic and colic tumors as well as in 
leukocytes and livers of tumor-bearing mice.34,35 
Thus, the production of ROS following surgery-
associated bacterial translocation in cancer patients 
with an imbalanced ROS-neutralizing system can 
result in damaged endothelial lining of the liver. 
We confirmed that LPS is an important factor for 
the induction of ROS production by macrophages. 
However, other bacterial components may be 
involved in enhancing tumor-cell adhesion, since 
the TLR1/2 ligand Pam3CSK4 as well as the TLR5 
ligand flagellin36 induced significant ROS produc-
tion by macrophages (Fig. S1). The TLR2 ligand 
peptidoglycan from Staphylococcus aureus did not 
induce ROS production. Thus, surgery may lead 
to contamination with different TLR ligands that 
may be involved in enhanced tumor-cell adhesion.
Because we previously demonstrated that 
enhanced tumor-cell adherence promotes the devel-
opment of liver metastases,8 we also investigated 
tumor development after LPS injection. In spite 
of increased tumor-cell adhesion, rats that received 
LPS developed less liver metastases as compared 
with PBS treated rats (data not shown). Previous 
studies demonstrated that LPS injection leads to 
tumor outgrowth from HT29 or 4T1 cells.14,15 
However, HT29 cells were grown in immunocom-
promised mice and 4T1 cells are poorly immuno-
genic, whereas CC531s cells have been reported to 
induce immune responses.8,37–40 Since TLR ligands can induce 
antitumor immunity,41–43 we stained tumor samples for infil-
trating CD8+ and CD4+ T cells as well as NK cells (data not 
shown). Tumors from the livers of rats that were treated with LPS 
contained significantly higher numbers of all these cell popula-
tions, suggesting that LPS stimulates immune responses against 
immunogenic CC531s cells, resulting in the inhibition of liver 
metastases. Alternatively, it is possible that the result of the study 
similar mechanisms to adhere to the liver ECM exposed upon 
damage of the microvasculature. Importantly, the downregula-
tion of endothelial tight junction molecules (reflecting a situation 
of endothelial cell stress) in liver samples of patients after sur-
gery has been reported, indicating that the exposure of the sub-
endothelial ECM after surgery can occur in patients as well.11 
Furthermore, enhanced numbers of circulating tumor cells dur-
ing surgery have been detected in CRC patients.9,10,32 Therefore, 
Figure 5. Lps-induced damage is mediated by ROs. (A) co-culture of hUVecs and macro-
phages (MΦ) were incubated with 100 ng/mL Lps in the presence or absence of catalase 
and/or sOD. Red, hUVecs; blue, cell nuclei. Dotted lines indicate areas without endothe-
lial cells. (B) Quantification of damaged endothelial area (%). *p < 0.05; **p < 0.01.
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employing 4T1 mammary carcinoma cells were 
affected by endotoxin tolerance, resulting in the unre-
sponsiveness of the immune system, as a five times 
higher concentration of LPS was used.44–46
In conclusion, LPS exposure can have opposing 
effects on tumor-cell adherence and tumor develop-
ment. First, by binding to TLR4, LPS induces the 
production of ROS by macrophages, hence initiat-
ing endothelial damage and promoting the exposure 
of the sub-endothelial ECM, to which circulating 
tumor cells can adhere. Second, LPS may stimulate 
the clearance of immunogenic tumor cells by pro-
moting the initiation of adaptive immune responses. 
However, the lack of specific tumor-associated anti-
gens is a major problem in most clinically manifest 
tumors.47 Therefore, it is likely that many patients 
may not benefit from LPS-induced antitumor 
immune responses because tumor antigens are poorly 
recognized by immune cells. Additionally, exposure 
to high LPS concentrations—as it occurs during 
anastomotic leakage—may induce endotoxin toler-
ance, explaining (at least in part) the poor survival 
of these patients. Increased understanding of the 
short-term and long-term activation of immune cells 
after surgery may help to identify patients at risk for 
the development of post-surgical liver metastases. 
Designing suitable peri-operative therapies to reduce 
this risk may ultimately improve disease outcome in 
cancer patients undergoing surgical resection.
Material and Methods
Colon carcinoma cell culture. The rat colon carci-
noma cell line CC531s is a moderately differentiated 
and immunogenic cell line.48 CC531s cells were cul-
tured under standard culture conditions in RPMI 
1640 medium (Invitrogen) supplemented with 10% 
heat-inactivated fetal calf serum (FCS), 2 mM glu-
tamine, 50 U/mL penicillin and 50 U/mL strepto-
mycin (Gibco; hereafter referred as CC531s complete 
growth medium). The human colon carcinoma cell 
line SW620 (ATCC) was cultured in DMEM (Gibco) 
containing 10% FCS (Gibco), 2 mM glutamine, 
50 U/mL penicillin and 50 U/mL streptomycin. Cell 
suspensions were prepared by enzymatic detachment 
Figure 6. Lps-induced tumor-cell adhesion in the liver is 
prevented by treatment with edaravone (eDa). (A) Tumor 
cells in the livers of rats that were treated with pBs, eDa, 
Lps or Lps plus eDa. Rats were sacrificed 1.5 h after tumor-
cell inoculation. Red, DiI-labeled cc531s cells; blue, cell 
nuclei, arrow heads point to cc531s cells (B) Quantification 
of the tumor cells in the livers of rats that were treated 
with pBs, eDa, Lps or Lps plus eDa. n = 4 per group; 
**p < 0.01; ***p < 0.001. (C) ZO-1 staining in the livers of 
rats that were either treated with pBs, eDa, Lps or Lps plus 
eDa. Green, ZO-1; blue, cell nuclei.
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Areas of damaged HUVECs monolayers were measured with 
AnalySIS software (Soft Imaging System GmbH).
Scanning and transmission electron microscopy (SEM and 
TEM). Freshly isolated human monocytes were allowed to differ-
entiate into macrophages for 7 d in macrophage growth medium 
in teflon Erlenmeyer flasks (Nalgene). Macrophages were 
seeded into 6-well culture plates (Greiner Bio One) and incu-
bated for different periods with PBS or 500 ng/mL LPS. SEM 
was performed as described previously.11 Alternatively, 1 h after 
incubation with PBS or LPS, macrophages were fixed in 2.5% 
glutaraldehyde, post-fixed with 1% osmium tetroxide, dehy-
drated in ethanol infiltrated with propylene oxide and embedded 
in Agar 100 Resin. Ultrathin sections were stained with uran-
ylacetate and leadcitrate and examined with TEM (Philips CM 
100 Bio Twin).
Animal models. Male inbred Wag/Rij rats (180–220 g) were 
housed under standard laboratory conditions and had access to 
food and water ad libitum. The Committee for Animal Research 
of the VUmc approved the experiments according to institutional 
and national guidelines.
Portal veins of rats were catheterized as described previously.8 
Catheters were flushed every 3 d with glycerol (Merck) contain-
ing heparin (50 IU/mL) to prevent obstruction of catheters by 
blood clots. All animals were allowed to recover 10 d. To inves-
tigate tumor-cell adhesion following an i.p. injection with PBS 
or 10 μg/kg LPS, 2 × 106 DiI-labeled CC531s cells were injected 
through the catheter and animals were sacrificed after 1.5 h (n 
= 4 per group). Liver samples were snap-frozen. In additional 
experiments, KCs were depleted by intravenous injection of clo-
dronate (Roche Diagnostics) encapsulated in liposomes25 or not 
(PBS administration), 2 d prior to tumor-cell injection (n = 4 
per group). Alternatively, rats received 125 mg/kg of the ROS 
scavenger edaravone (3-Methyl-1-Phenyl-2-Pyrazolin-5-one, 
Calbiochem, Darmstadt, Germany) or the vehicle ethanol (± 
6%) i.p. Thirty minutes prior to and immediately after LPS or 
PBS injection (n = 4 per group). Animals were sacrificed 1.5 h 
after inoculation of fluorescently labeled CC531s cells. Liver sam-
ples were snap frozen for immunofluorescent analyses.
Fluorescence microscopy. Cryostat liver tissue sections of 5 μm 
were fixed for 10 min in acetone and air-dried. After blocking 
with 10% normal goat serum for 15 min, slides were incubated for 
1 h with primary antibodies against ZO-1 (Zymed Laboratories) 
at RT. Rabbit serum was used as isotype control. After washing, 
visualization was achieved by incubation with Alexa 488-labeled 
secondary antibodies (Molecular Probes, Inc.). Nuclei were 
stained with Hoechst (Molecular Probes, Inc.). Sections were 
washed, mounted and examined with a Leica DM6000 fluores-
cence microscope (Leica Microsystems). Tumor-cell numbers at 
different time points after surgery were determined (20 stitched 
fields per liver sample, 5 liver samples per animal).
Statistical analyses. For comparisons between two groups 
Student’s t tests were used. Comparisons between multiple 
groups (> 2) were performed with ANOVA. Statistical signifi-
cance was accepted at p < 0.05. Results are presented as means 
± SEM.
using a trypsin-EDTA solution (Gibco), and contained single 
tumor cells as well as small clusters (2–8 cells). Viability was 
assessed by tryphan blue exclusion and always exceeded 95%. 
For in vivo experiments, CC531s cells (5 × 106 cells/mL) were 
fluorescently labeled by incubating cells in CC531s complete 
growth medium containing 50 μg/mL 1,1-dioctadecyl-3,3,3,3-
tetramethylindocarbo cyanine perchlorate (DiI, Sigma-Aldrich) 
for 30 min at 37°C and subsequently washed with HBSS (Gibco) 
according to the manufacturer’s instructions. SW620 cells 
(4.5 × 106 cells/mL) were fluorescently labeled by incubation at 
37°C for 20 min in DMEM/ supplemented with 10% FCS and 
containing calcein-AM (0.5 μM, Invitrogen), after which cells 
were washed with Hanks’ balanced salt solution containing 0.5% 
bovine serum albumin and diluted (2 × 106 cells/mL).
Endothelial cell cultures. Human umbilical veins were treated 
with collagenase (Worthington) for 20 min at 37°C according to 
a standard procedure.49 HUVECs were harvested and cultured 
to confluence till passage 5 in M199 medium supplemented with 
10% heat-inactivated human serum, 10% heat-inactivated new 
born calf serum, 5000 U/mL heparin, 10 μg/mL basic fibroblast 
growth factor (Peprotech Inc.), 2 mM glutamine, 50 U/mL peni-
cillin and 50 U/mL streptomycin (Gibco) in standard culture 
conditions (hereafter referred to as endothelial growth medium).
Endothelial-macrophage co-cultures. Monocytes were iso-
lated with CD14 MicroBeads (MACS Miltenyi Biotec) from 
freshly obtained donor blood, according to the manufacturer’s 
instructions. All healthy donors gave informed consent accord-
ing to the guidelines of the medical ethical committee of the 
VUmc. Cells were resuspended in DMEM medium containing 
10% heat-inactivated human serum, 2 mM glutamine, 50 U/mL 
penicillin and 50 U/mL streptomycin (Gibco; referred as mac-
rophage growth medium). 2 × 105 monocytes were added to 
transwells (Corning Inc.) with 0.4 μm pore size polyester mem-
brane inserts, which had been turned upside down. Transwells 
were incubated for 3 h to allow optimal adhesion of monocytes 
to membranes (on bottom side). Transwells were then turned 
and placed in 24 well plates for 7 d to allow differentiation into 
macrophages in macrophage growth medium. Hereafter, conflu-
ent HUVEC monolayers (5 × 105 cells/well) were cultured on 
gelatine coating on the upper site of filters. Cells were incubated 
with different concentrations of LPS for 30 min in M199 with or 
without the LPS scavenger polymyxin B sulfate (PMB, 50 μg/
mL, Applichem). Alternatively, 5000 U/mL SOD (from bovine 
erythrocytes, Sigma Aldrich) and catalase (from bovine liver, 
Sigma Aldrich) were added.
Tumor-cell adhesion after exposure to LPS of HUVEC-
macrophage co-cultures was investigated by adding 2 × 105 cal-
cein-labeled SW620 cells, which were allowed to adhere for 30 
min at 37°C. After washing, cells were fixated with 1% glutaral-
dehyde for 10 min at room temperature (RT). HUVECs mono-
layers were stained with Rhodamine-labeled Ulex Europaeus 
Agglutinin I (Vectors Labs) for 15 min at RT. Cell nuclei were 
stained with Hoechst (Invitrogen). Membranes were washed, 
removed from the inserts, mounted and 5 random pictures were 
made with a Leica DM6000 microscope (Leica Microsystems). 
www.landesbioscience.com OncoImmunology 1525
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Amsterdam, the Netherlands) for facilitating electron micros-
copy experiments.
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